Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab + Durvalumab + Chemotherapy in First-Line Extensive Stage Small-Cell Lung Cancer
NCT07005128Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 26
01
Overview
A Phase 3 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Aug 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07005128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005128.